Abstract
The Parkinson’s Progression Markers Initiative (PPMI) delivers multiple modality MRI (M3RI) and biomarker data for a comprehensive longitudinal study of Parkinson’s Disease (PD). These provide quantitative indices of deep brain and cortical structure (T1-weighted MRI), microstructural integrity of brain tissue (diffusion-weighted imaging) and resting brain function (resting state functional MRI). Integrating and uniformly analyzing M3RI alongside non-imaging biological and clinical data is challenging due to the distinct nature of each modality. This study systematically organizes these complex data into a structured format, provides a PD-focused evaluation of the methodologies and evidence for technical robustness of the approach. The cohort encompasses 841 idiopathic PD, 309 genetic PD, 1364 presymptomatic PD and 240 control subjects at baseline with followup at a mean of 1.83 years.
Competing Interest Statement
BA declares research support and consulting fees from The Michael J Fox Foundation. LMC declares research support and consulting fees from The Michael J Fox Foundation. KP declares consultancies for Curasen; was on a scientific advisory board for Curasen and Amprion; honoraria from invited scientific presentations to universities and professional societies not exceeding $5000 per year from California Congress of Clinical Neurology, California Neurological Society, and Johns Hopkins University; and patents or patent applications numbers 17/314,979 and 63/377,293. KP also declares grants to her institution (Stanford University School of Medicine) from NIH/NINDS NS115114, NS062684, NS075097, NIH/NIA U19 AG065156, P30 AG066515, The Michael J Fox Foundation, Lewy Body Dementia Association, Alzheimers Drug Discovery Foundation, Sue Berghoff LBD Research Fellowship, and the Knight Initiative for Brain Resilience. KM declares support to his institution (Institute for Neurodegenerative Disorders) from The Michael J Fox Foundation. KM also declares consultancies for Invicro, The Michael J Fox Foundation, Roche, Calico, Coave, Neuron23, Orbimed, Biohaven, Anofi, Koneksa, Merck, Lilly, Inhibikase, Neuramedy, IRLabs, and Prothena. KM participates on DSMB at Biohaven.
Funding Statement
Our sincere appreciation to the Michael J. Fox Foundation (MJFF) for supporting this work through MJFF-021144. Technical development for aspects of the software used in this work are supported by the Office of Naval Reseach ONR Award Number: N00014-23-1-2317.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://ida.loni.usc.edu/login.jsp?project=PPMI contains the source data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data Availability
All data produced in the present study are available upon reasonable request to the authors
